Milan, Italy and Morristown, NJ, USA - May 29, 2018 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Milan, Italy and Morristown, NJ, USA - May 15, 2018 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel
Milan, Italy – March 27, 2018 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Milan, Italy, March 1, 2018 – Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the
Sponsoring Comprehensive Study to Examine the Burden of Rett Syndrome on Patients and Caregivers; Supporting Standardized Methodology for Health Economic Assessment of Orphan
Milan, Italy – February 8, 2018 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, CEO: Daikichiro Kobayashi, “Meiji”) announced today that
Milan, Italy - November 14, 2017 - Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients
- Advisory Board Characterizes Illness and Treatment Patterns
- Rett Congress Reviews Multi-Organ Impact of Single Symptoms
Milan, Italy & Morristown, N.J. – November 7, 2017
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
